focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Income is separate from capital gain tax. But please seek professional advice as I am not qualified to provide. ;-)
Only if your total gain is outside of annual CGT allowance. Gains are not realized until sold.
I honestly don’t understand why some will wait until the 6th April to use their tax allowance when you can simply ‘bed and isa’ for which the 30 day rule means that the sale and repurchase of shares during this period count as the same asset and therefore do not qualify for Capital Gains Tax.
For me this is what has presented such an intriguing opportunity at these levels. Many have reduced their position or exited in anticipation of lower prices and in all honesty they have discounted the impact of upcoming commercial catalysts such as the labs and ovarian results.
Labs
Research based revenue expected to be high single digit millions. Pharma services revenue high enough to cover entire corporate costs within circ. 5 years and then you have the clear lab assays such as breast and ovarian which are multi Billion dollar opportunities.
We are to receive an update on the Pdl-1 assay which again is another massive market opportunity, all of which feeds into large Pharma contracts.
A temporary spike, not for me, commercial progress is what the market has been waiting for, it’s the start of a very exciting story.
Bargain
Which is the current ovarian cancer test of choice for many including NHS and costs $200 a test or more, it has a lower specificity and sensitivity than Parsortix, so in theory it should be relatively straight forward to gain market share for this diagnostic.
Breast cancer test HER2 trial was also designed to satisfy CE approval and an application for this will be made shortly after FDA approval.
Verification study is due Q2 and as far as I’m aware June. Company will aim to launch assay by year end.
In all honesty the little volume on the OTC listing has little relevance at this stage but I do believe the Nasdaq listing is just awaiting the FDA decision now before they officially list on Nasdaq. An Abbott or similar partnership would also present better value in terms of dilution.
Ovarian cancer assay which is a $2 billion annual opportunity and would have the highest sensitivity and specificity (gold standard) has also not been partnered at this stage which will present real value by year end.
I think the lab news and the subsequent Pharma contracts are being completely discounted at this price.
Pharma services ‘alone’ are said to cover the entire companies costs circ. 5 years. They have a formidable workforce at AGL just waiting to facilitate a high period of growth.
Momentum is shifting and we are lucky enough to now play this ride and the Ovarian results before the FDA decision which has seen its perceived risk substantially reduced.
AGL has this and so much more to look forward, but this period of cooling off has done no harm to the longer term trajectory.
It has been said that the US understand the FDA process far better than us brits, and as has been eluded to, this request for information was ‘as expected’ and that they were on track for Q2. Only for a delay similar to that of others who have seen a comparitively small drop in the share price, this has presented one hell of an opportunity to buy more, an opportunity that I believe active US investors will also be keen to take advantage of.
- Pharma labs UK and US
- Pharma Contracts
- Ovarian Cancer Study
- Nasdaq listing
- Partnerships
- FDA decision
- Sample to answer upgrade
- Peer reviewed papers
- Ovarian cancer assay by year end
Plenty of corporate milestones to keep us entertained and more importantly to underpin the company and its future global multi billion dollar opportunities.
De-risked on the basis that in the event they were unable to answer the written question within 180 days they would have to withdraw the application, that is a massive milestone that didn’t come to the fore.
Also no requirements for bloods, and path to submission of data becoming of May. This also suggests that they are happy with data (bloods), another massive tick.
FDA is certainly not a profit taking event as large corporate partnerships then open up, if they haven’t already. Will be buying every time I can afford to until market cap reaches something approaching a reasonable valuation compared to its peers. This is certainly not this side of £1b and will follow the Nasdaq listing.
Can you imagine what national coverage would do to this.
Less than 120 seconds, now that is hard to ignore, especially taking the current market cap into consideration.
I am lost, what’s down 2P?
Looking at L2 and the book is strengthening
“The project...has reached a stage where manufacture of the new vaccine has begun.”
This will have a use by date that for me further signifies imminent trials.
With current demand for stock at this level I wouldn’t be surprised to see an RNS tomorrow
Already had a speeding ticket, this is open sky
Willingness to take significant stock in one trade, something that hasn’t been the case for most of the day, I have been doing some dummy sells from this morning to test the market.
Fair number of my trades have not been reported from both today and yesterday, from what I have seen and certainly not in real time. I can only assume the same applies on the sell side. But what we do know is that when this shifts it shifts quickly with no explanation that we can ordinarily see in real time, making the above explanation a plausible reason.